Trial Profile
A Randomized, Double-blind Controlled Study to Determine the Effectiveness, Safety and Tolerability of Actoferon Compared to Betaferon in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Actover Pharmaceutical
- 09 Jul 2014 New trial record